Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

USA - NASDAQ:LEGN - US52490G1022 - ADR

32.5 USD
-0.32 (-0.98%)
Last: 9/26/2025, 10:23:05 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LEGN. LEGN was compared to 538 industry peers in the Biotechnology industry. LEGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LEGN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LEGN had negative earnings in the past year.
In the past year LEGN has reported a negative cash flow from operations.
In the past 5 years LEGN always reported negative net income.
LEGN had a negative operating cash flow in each of the past 5 years.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

The Return On Assets of LEGN (-19.25%) is better than 77.14% of its industry peers.
LEGN has a Return On Equity of -31.42%. This is in the better half of the industry: LEGN outperforms 76.39% of its industry peers.
Industry RankSector Rank
ROA -19.25%
ROE -31.42%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

Looking at the Gross Margin, with a value of 62.51%, LEGN is in the better half of the industry, outperforming 79.00% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

4

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEGN has more shares outstanding than it did 1 year ago.
LEGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, LEGN has a worse debt to assets ratio.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LEGN has an Altman-Z score of 7.12. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
LEGN has a better Altman-Z score (7.12) than 80.67% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that LEGN is not too dependend on debt financing.
LEGN has a worse Debt to Equity ratio (0.37) than 71.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 7.12
ROIC/WACCN/A
WACC9.61%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.71 indicates that LEGN has no problem at all paying its short term obligations.
LEGN's Current ratio of 4.71 is in line compared to the rest of the industry. LEGN outperforms 51.49% of its industry peers.
A Quick Ratio of 4.57 indicates that LEGN has no problem at all paying its short term obligations.
LEGN's Quick ratio of 4.57 is in line compared to the rest of the industry. LEGN outperforms 52.23% of its industry peers.
Industry RankSector Rank
Current Ratio 4.71
Quick Ratio 4.57
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

7

3. Growth

3.1 Past

LEGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.18%.
Looking at the last year, LEGN shows a very strong growth in Revenue. The Revenue has grown by 74.75%.
Measured over the past years, LEGN shows a very strong growth in Revenue. The Revenue has been growing by 59.90% on average per year.
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-580%
Revenue 1Y (TTM)74.75%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%36.74%

3.2 Future

Based on estimates for the next years, LEGN will show a very strong growth in Earnings Per Share. The EPS will grow by 37.58% on average per year.
Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 36.23% on average per year.
EPS Next Y7.73%
EPS Next 2Y62.64%
EPS Next 3Y44.97%
EPS Next 5Y37.58%
Revenue Next Year68.18%
Revenue Next 2Y60.27%
Revenue Next 3Y51.3%
Revenue Next 5Y36.23%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEGN. In the last year negative earnings were reported.
LEGN is valuated quite expensively with a Price/Forward Earnings ratio of 53.04.
Based on the Price/Forward Earnings ratio, LEGN is valued cheaper than 89.22% of the companies in the same industry.
LEGN is valuated expensively when we compare the Price/Forward Earnings ratio to 22.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 53.04
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
LEGN's earnings are expected to grow with 44.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.64%
EPS Next 3Y44.97%

More info and screens

0

5. Dividend

5.1 Amount

LEGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (9/26/2025, 10:23:05 AM)

32.5

-0.32 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners47.87%
Inst Owner Change-3.54%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap5.96B
Analysts83.08
Price Target77.3 (137.85%)
Short Float %8.68%
Short Ratio6.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-239.55%
Min EPS beat(2)-351.12%
Max EPS beat(2)-127.98%
EPS beat(4)1
Avg EPS beat(4)-96.8%
Min EPS beat(4)-351.12%
Max EPS beat(4)143.99%
EPS beat(8)5
Avg EPS beat(8)-30.97%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)9.2%
Revenue beat(4)3
Avg Revenue beat(4)4.83%
Min Revenue beat(4)-1.23%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.64%
PT rev (3m)-2.17%
EPS NQ rev (1m)-33.54%
EPS NQ rev (3m)-45.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-40.45%
Revenue NQ rev (1m)-1.95%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)-0.84%
Revenue NY rev (3m)2.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 53.04
P/S 7.48
P/FCF N/A
P/OCF N/A
P/B 5.76
P/tB 5.77
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)0.61
Fwd EY1.89%
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS4.34
BVpS5.64
TBVpS5.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.25%
ROE -31.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.51%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.19%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.71
Quick Ratio 4.57
Altman-Z 7.12
F-Score3
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-580%
EPS Next Y7.73%
EPS Next 2Y62.64%
EPS Next 3Y44.97%
EPS Next 5Y37.58%
Revenue 1Y (TTM)74.75%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%36.74%
Revenue Next Year68.18%
Revenue Next 2Y60.27%
Revenue Next 3Y51.3%
Revenue Next 5Y36.23%
EBIT growth 1Y41.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.34%
EBIT Next 3Y60.83%
EBIT Next 5Y36.12%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A